NRIX Valuation

Nurix Therapeutics Inc

Add to Watchlist

Advanced Chart

11.520

-0.01(-0.087%)1D

Overview
Forecast
Valuation
Earnings

NRIX Relative Valuation

NRIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NRIX is overvalued; if below, it's undervalued.

Historical Valuation

Nurix Therapeutics Inc (NRIX) is now in the Fair zone, suggesting that its current forward PS ratio of 14.46 is considered Fairly compared with the five-year average of -6.79. The fair price of Nurix Therapeutics Inc (NRIX) is between 5.84 to 22.14 according to relative valuation methord.

Relative Value

Fair Zone

5.84-22.14

Current Price：11.53

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.99

P/B

Median3y

2.48

Median5y

2.80

-25.39

FCF Yield

Median3y

-23.80

Median5y

-17.27

Competitors Valuation Multiple

The average P/S ratio for NRIX's competitors is 7.54, providing a benchmark for relative valuation. Nurix Therapeutics Inc Corp (NRIX) exhibits a P/S ratio of 14.46, which is 91.71% above the industry average. Given its robust revenue growth of 264.34%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NRIX.O

Nurix Therapeutics Inc

14.46

Average P/S: 7.54

264.34%